COVID-19 has significantly and adversely affected preclinical research and clinical trials across the universe of life science companies as a result of the suspension of elective procedures in the U.S. and globally, as well as the challenges posed by travel bans, the furlough of or requirement that clinical study personnel work remotely, restrictions on access to hospitals and laboratories for clinical research professionals, as well as social distancing precautions.

Nevertheless, Minneapolis-based VentureMed and its preclinical research partner, Boston-area-based CBSET, were able to overcome these obstacles with laser focus and a mutual determination to continue the momentum and progress on an important research project for VentureMed.